A randomized phase Ib/II study of enzalutamide (Enza) with and without ribociclib (Rib) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that retains RB expression: RiboX study.
Publication/Presentation Date
5-2026
Volume
44
Issue
16
First Page
5057
Last Page
5057
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS